Gyre Therapeutics, Inc. (GYRE)
 NASDAQ: GYRE · Real-Time Price · USD
 7.65
 +0.11 (1.46%)
  Oct 30, 2025, 4:00 PM EDT - Market closed
Gyre Therapeutics Employees
Gyre Therapeutics had 579 employees as of December 31, 2024. The number of employees decreased by 14 or -2.36% compared to the previous year.
Employees 
 579
Change (1Y) 
 -14
Growth (1Y) 
 -2.36%
Revenue / Employee 
 $176,492
Profits / Employee 
 $7,193
Market Cap 
694.82M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 579 | -14 | -2.36% | 
| Dec 31, 2023 | 593 | - | - | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
GYRE News
- 15 days ago - Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis - GlobeNewsWire
- 16 days ago - Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025 - GlobeNewsWire
- 7 weeks ago - Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker - Benzinga
- 2 months ago - Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors - GlobeNewsWire
- 2 months ago - Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update - GlobeNewsWire
- 5 months ago - Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China - GlobeNewsWire
- 5 months ago - Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire